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Sir,
We have read with interest the paper by Cordonnier et al.1 intro-
ducing the European Conference on Infections in Leukemia (ECIL)
guidelines for Pneumocystis jirovecii pneumonia (PJP), and would
like to comment on some assertions that we believe are some-
what outdated or not fully correct.
First of all, the authors repeat the old mantra that the
‘transmission of P. jirovecii occurs during the first years of life
via person-to-person contact’, and that ‘two-thirds of immuno-
competent individuals have specific antibodies by the age of 4
years’.1 At the beginning of the AIDS pandemic, this assump-
tion, which is based on many now-dated studies of healthy
children, led to the formulation of the long-lived ‘reactivation
theory’: i.e. PJP is the consequence of a reactivation of long-
term colonization, and the disease develops when the immune
system is profoundly affected by HIV infection or another con-
dition causing immunodeficiency.2 However, this theory has
been challenged by Yiannakis and Boswell3 in a recent review
of 30 outbreaks occurring among kidney transplant patients
and patients with haematological malignancies: extensive mo-
lecular genotyping of a number of these outbreaks indicates
de novo acquisition from an environmental source or patient-
to-patient transmission. Furthermore, Choukri et al.4 have dem-
onstrated that the aerosol dispersion of P. jirovecii DNA into
the environment occurs up to 8 m from a patient with PJP,
and an elegant study by Gits-Muselli et al.5 found a single
genotype among PJP patients sharing the same hospital envir-
onment. These findings raise the question of controlling hos-
pital infections among immunocompromised patients, and the
CDC has recommended that a patient with confirmed PJP
should not share a room with another immunocompromised
patient.6
The second point we would like to discuss is the reported
clinical differences between HIV-positive and HIV-negative pa-
tients. The authors state that hypoxaemia is ‘mild’ among HIV-
positive patients but ‘often severe’ among HIV-negative pa-
tients. However, the studies supporting this view are based on
small sample sizes or unbalanced groups: Mansharamani et al.7
compared 442 HIV-positive patients with 33 HIV-negative pa-
tients; Kovacs et al.8 considered 49 episodes in AIDS patients
and 39 episodes in other immunosuppressed patients; and
Limper et al.9 compared 19 AIDS patients with 56 patients
without AIDS. Moreover, the HIV-negative populations in these
studies included patients with heterogeneous immunosuppres-
sive conditions (i.e. haematological or solid malignancies, ster-
oid therapy, solid organ transplantation and primary
immunodeficiency), and extrapolating the findings to haemato-
logical patients alone may not be appropriate. It is also clear
that the time to medical attention and to treatment initiation
is critically important in determining the evolution of hypoxa-
emia and the related PaO2 values of PJP patients, regardless of
underlying clinical condition. As shown in Table 1, we found ad-
mission PaO2 values were ,60 mmHg in 37.4% of our 468 pa-
tients experiencing a first episode of HIV-associated PJP
confirmed by bronchoalveolar lavage and/or autopsy, and 60–
70 mmHg in a further 27.1% (Table 1). Furthermore, during
hospitalization, 51.1% of the patients required adjunctive ster-
oids, 31.0% required continuous positive airway pressure
therapy and 4.9% were intubated and mechanically ventilated
in our ICU.
We also do not agree with the statement based on the
findings of McKinnell et al.10 and Vogel et al.11 that high lactate
dehydrogenase (LDH) levels are more specific and sensitive in
HIV-positive than in HIV-negative patients. McKinnell et al.10
found no difference in LDH levels between the two groups (496
+ 50.5 IU/L versus 354.9 + 29.2 IU/L; P " 0.10), and no differ-
ence in hypoxaemia, dyspnoea or the rate of mechanical venti-
lation. Moreover, the sensitivity and specificity values of high
LDH levels in HIV-positive patients reported by Vogel et al.11
were obtained in a very small sample of only eight patients.
Twenty-one percent of our 468 patients had normal LDH val-
ues, whereas the highest median levels were observed among
those patients who had concurrent AIDS-related or AIDS-
unrelated malignancies (particularly lymphomas). Given the
high LDH levels often observed among patients with several
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types of cancers, it may not be appropriate to use them as the
basis for a suspicion of PJP, even in the context of HIV
infection.
Finally, the 17%–30% mortality rate of HIV-positive patients
shown in Table 2 of the paper by Cordonnier et al.1 refers to studies
conducted during the 1980s and early 1990s. Our early mortality
rate of ,5% confirms other reports12 that the mortality of
HIV-positive patients with PJP has significantly decreased since
then due to the effects of HAART or to general improvements in
ICU care.
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Table 1. Characteristics of first episodes of HIV-related PJP observed at
the Clinic of Infectious Diseases, Luigi Sacco Hospital, Milan, between
January 1985 and June 2016; N" 468
Characteristic
Period of PJP diagnosis, n (%)
before 1997 276 (59)
after 1997 192 (41)
Gender, n (%)
males 356 (76)
females 112 (24)
Age (years), median (range) 35 (21–75)
Characteristics of HIV infection, n (%)
known HIV infection prior to PJP diagnosis 123 (26.3)
blood CD4 cells/lL
,200 455 (97.2)
,50 298 (63.7)
PJP prophylaxis administered 65 (13.9)
AIDS-related comorbidities at time of PJP
diagnosis
269 (57.5)
Clinical characteristics of PJP
PaO2 breathing room air upon admission, n (%)
,60 mmHg 175 (37.4)
60–70 mmHg 127 (27.1)
.71 mmHg 166 (35.5)
serum LDH level (IU/L), median (range) 728 (98-5710)
normal serum LDH level, n (%) 98 (20.9)
serum LDH level in patients with concurrent
neoplasia (IU/L) (n" 49), median (range)
854 (160–5710)
serum LDH level in patients with concurrent
lymphoma (IU/L) (n" 18), median (range)
1279 (431–5710)
radiographic pattern, n (%)
interstitial 316 (67.5)
alveolar 88 (18.8)
mixed 37 (7.9)
normal 27 (5.8)
presence of cysts or pneumothorax 15 (3.2)
presence of pleural effusion 8 (1.7)
initial treatment with trimethoprim/sulfa-
methoxazole, n (%)
402 (85.9)
adjunctive corticosteroids, n (%) 239 (51.1)
continuous positive airway pressure ther-
apy required, n (%)
145 (31.0)
mechanical ventilation required, n (%) 23 (4.9)
30 day mortality, n (%)
before 1997 38 (13.8)
after 1997 9 (4.7)
Letters to the Editor JAC
1265
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/72/4/1264/2643170 by guest on 16 O
ctober 2019
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antiretroviral therapy in HIV-infected patients with severe Pneumocystis cari-
nii pneumonia.AIDS2003;17: 73–80.
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Sir,
We would like to thank Antinori et al.1 for their comments on the
European Conference on Infections in Leukemia (ECIL) guidelines
for the management of Pneumocystis jirovecii pneumonia (PCP).2
Antinori et al.1 listed four points, which we would like to address
one by one.
Mode of acquisition of PCP in haematology patients
The mode of acquisition of PCP in haematology patients is uncertain, but
there is no reason to think that it is different from that in other immunocom-
promised patients. Exposure to P. jirovecii through inhalation begins early in
life, as shown by autopsy series, and PCR and serological screenings.3–6 The
high rate of mixtures of genotypes during PCP (up to 90%) also supports con-
tinuous exposure to P. jirovecii from the environment via other humans.7
When investigating outbreaks in solid organ transplant units using genotyp-
ing, only some of the cases were shown to be due to inter-human or environ-
mental transmission.8,9 To our knowledge, only two outbreaks have been
reported in haematology wards. The first one included five cases in 6 months
in the same haematology unit, but without any molecular investigation.10
The second study established a genetic link using internal transcribed spacer
(ITS) sequencing between the strains for two out of eight haematology pa-
tients (and two out of six HIV-positive patients), suggesting that person-to-
person transmission was relatively infrequent.11 Recently, transmission be-
tween patients from different wards was reported with the help of six new
short tandem repeat markers located in the nuclear genome.12 However,
even with this highly discriminant genotyping method, we could not differen-
tiate between reactivation and a new infection.12 Despite the lack of solid
data reflected by a grading of only C-III, ECIL proposed that patients in
haematology should, nonetheless, avoid contact with those infected with
PCP.13
Differences in clinical presentation and hypoxaemia
between patients with and without HIV infection
Antorini et al.1 show that two-thirds of their patients with HIV infection had a
PaO2,70 mmHg. However, the PaO2 of patients with PCP, but without HIV in-
fection, was not presented. This makes any conclusion about PaO2 at diagno-
sis difficult. We agree with Antorini et al.1 that PaO2 at presentation can be
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